235 related articles for article (PubMed ID: 31996893)
1. WDR5 is a conserved regulator of protein synthesis gene expression.
Bryan AF; Wang J; Howard GC; Guarnaccia AD; Woodley CM; Aho ER; Rellinger EJ; Matlock BK; Flaherty DK; Lorey SL; Chung DH; Fesik SW; Liu Q; Weissmiller AM; Tansey WP
Nucleic Acids Res; 2020 Apr; 48(6):2924-2941. PubMed ID: 31996893
[TBL] [Abstract][Full Text] [Related]
2. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity.
Aho ER; Wang J; Gogliotti RD; Howard GC; Phan J; Acharya P; Macdonald JD; Cheng K; Lorey SL; Lu B; Wenzel S; Foshage AM; Alvarado J; Wang F; Shaw JG; Zhao B; Weissmiller AM; Thomas LR; Vakoc CR; Hall MD; Hiebert SW; Liu Q; Stauffer SR; Fesik SW; Tansey WP
Cell Rep; 2019 Mar; 26(11):2916-2928.e13. PubMed ID: 30865883
[TBL] [Abstract][Full Text] [Related]
3. WIN site inhibition disrupts a subset of WDR5 function.
Siladi AJ; Wang J; Florian AC; Thomas LR; Creighton JH; Matlock BK; Flaherty DK; Lorey SL; Howard GC; Fesik SW; Weissmiller AM; Liu Q; Tansey WP
Sci Rep; 2022 Feb; 12(1):1848. PubMed ID: 35115608
[TBL] [Abstract][Full Text] [Related]
4. Impact of WIN site inhibitor on the WDR5 interactome.
Guarnaccia AD; Rose KL; Wang J; Zhao B; Popay TM; Wang CE; Guerrazzi K; Hill S; Woodley CM; Hansen TJ; Lorey SL; Shaw JG; Payne WG; Weissmiller AM; Olejniczak ET; Fesik SW; Liu Q; Tansey WP
Cell Rep; 2021 Jan; 34(3):108636. PubMed ID: 33472061
[TBL] [Abstract][Full Text] [Related]
5. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
Elife; 2024 Apr; 12():. PubMed ID: 38682900
[TBL] [Abstract][Full Text] [Related]
6. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.
Ding J; Li G; Liu H; Liu L; Lin Y; Gao J; Zhou G; Shen L; Zhao M; Yu Y; Guo W; Hommel U; Ottl J; Blank J; Aubin N; Wei Y; He H; Sage DR; Atadja PW; Li E; Jain RK; Tallarico JA; Canham SM; Chiang YL; Wang H
ACS Chem Biol; 2023 Jan; 18(1):34-40. PubMed ID: 36594833
[TBL] [Abstract][Full Text] [Related]
8. Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells.
Florian AC; Woodley CM; Wang J; Grieb BC; Slota MJ; Guerrazzi K; Hsu CY; Matlock BK; Flaherty DK; Lorey SL; Fesik SW; Howard GC; Liu Q; Weissmiller AM; Tansey WP
NAR Cancer; 2022 Mar; 4(1):zcac007. PubMed ID: 35252869
[TBL] [Abstract][Full Text] [Related]
9. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance.
Thomas LR; Adams CM; Wang J; Weissmiller AM; Creighton J; Lorey SL; Liu Q; Fesik SW; Eischen CM; Tansey WP
Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25260-25268. PubMed ID: 31767764
[TBL] [Abstract][Full Text] [Related]
10. p53 inactivation unmasks histone methylation-independent WDR5 functions that drive self-renewal and differentiation of pluripotent stem cells.
Li Q; Huang Y; Xu J; Mao F; Zhou B; Sun L; Basinski BW; Aksu M; Liu J; Dou Y; Rao RC
Stem Cell Reports; 2021 Nov; 16(11):2642-2658. PubMed ID: 34715053
[TBL] [Abstract][Full Text] [Related]
11. WDR5 facilitates recruitment of N-MYC to conserved WDR5 gene targets in neuroblastoma cell lines.
Bumpous LA; Moe KC; Wang J; Carver LA; Williams AG; Romer AS; Scobee JD; Maxwell JN; Jones CA; Chung DH; Tansey WP; Liu Q; Weissmiller AM
Oncogenesis; 2023 Jun; 12(1):32. PubMed ID: 37336886
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW
J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H
J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
15. Structural studies of WDR5 in complex with MBD3C WIN motif reveal a unique binding mode.
Yang Y; Xu L; Zhang S; Yao L; Ding Y; Li W; Chen X
J Biol Chem; 2024 Jun; ():107468. PubMed ID: 38876301
[TBL] [Abstract][Full Text] [Related]
16. METTL3 orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in triple-negative breast cancer.
Yuan XN; Shao YC; Guan XQ; Liu Q; Chu MF; Yang ZL; Li H; Zhao S; Tian YH; Zhang JW; Wei L
Biochim Biophys Acta Mol Cell Res; 2024 Jun; 1871(5):119716. PubMed ID: 38547933
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of the multitasking high-affinity Win binding site of WDR5 in restricted and unrestricted conditions.
Imran A; Moyer BS; Canning AJ; Kalina D; Duncan TM; Moody KJ; Wolfe AJ; Cosgrove MS; Movileanu L
Biochem J; 2021 Jun; 478(11):2145-2161. PubMed ID: 34032265
[TBL] [Abstract][Full Text] [Related]
18. A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex.
Patel A; Vought VE; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32162-75. PubMed ID: 18829457
[TBL] [Abstract][Full Text] [Related]
19. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik SW; Liu Q; Tansey WP
bioRxiv; 2024 Jan; ():. PubMed ID: 37546802
[TBL] [Abstract][Full Text] [Related]
20. p53 Integrates Temporal WDR5 Inputs during Neuroectoderm and Mesoderm Differentiation of Mouse Embryonic Stem Cells.
Li Q; Mao F; Zhou B; Huang Y; Zou Z; denDekker AD; Xu J; Hou S; Liu J; Dou Y; Rao RC
Cell Rep; 2020 Jan; 30(2):465-480.e6. PubMed ID: 31940490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]